Chiasma Inc.

75 articles about Chiasma Inc.

• Israeli Biotech Chiasma Reels in $70 Million Despite Roche Pullout

  2/27/2015

• Chiasma Inc. Appoints David Stack As Chairman Of The Board; John A. Scarlett, M.D. Joins Board Of Directors

  2/24/2015

• Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder

  2/9/2015

• Despite Roche Dropping $595 Million Deal, Chiasma Bags $33.8 Million

  1/2/2015

• Roche Backs Out Of $600 Million Acromegaly Drug Development Deal With Chiasma Inc.

  8/14/2014

• Roche and Chiasma Inc. to Ally on Drug Development for Up to $600 Million

  2/20/2013

• Chiasma Inc. Closes $38.5 Million Equity Financing

  7/23/2012

• Chiasma Inc. Release: Data on Investigational Oral Octreolin&#0153 for Acromegaly Demonstrate Growth Hormone Suppression

  6/27/2012

• Chiasma Inc. to Present at the UBS Global Life Sciences Conference

  9/14/2011

• Chiasma Inc.'s Octreolin(TM) (Oral Octreotide) Shown to Inhibit Growth Hormone in Healthy Subjects

  6/6/2011

• Chiasma Inc. to Present at the UBS Global Life Sciences Conference

  9/21/2010

• Chiasma (Israel) Ltd. Receives Orphan Drug Designation From the FDA for Octreolin(TM) for the Oral Treatment of Acromegaly

  6/28/2010

• Chiasma Secures $11 Million

  1/13/2009

• Chiasma Raises $44 Million Series C To Fund Clinical Testing, Advance Technology

  11/15/2006

• Chiasma Inc. Completes $6.2M Series B Round; New US Operations In Boston

  9/12/2005